Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $797.57 +0.43%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Fredonia Mining PEA estimates $1.49B NPV for Argentina gold project
- Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
